S
Sebastian Grosicki
Researcher at Medical University of Silesia
Publications - 225
Citations - 9981
Sebastian Grosicki is an academic researcher from Medical University of Silesia. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 33, co-authored 185 publications receiving 7488 citations. Previous affiliations of Sebastian Grosicki include University Hospitals of Leicester NHS Trust & University of Silesia in Katowice.
Papers
More filters
Journal ArticleDOI
Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia
Jan A. Burger,Alessandra Tedeschi,Paul M. Barr,Tadeusz Robak,Carolyn Owen,Paolo Ghia,Osnat Bairey,Peter Hillmen,Nancy L. Bartlett,Jianyong Li,David Simpson,Sebastian Grosicki,Stephen Devereux,Helen McCarthy,Steven Coutre,Hang Quach,Gianluca Gaidano,Zvenyslava Maslyak,Don A. Stevens,Ann Janssens,Fritz Offner,Jiří Mayer,Michael O'Dwyer,Andrzej Hellmann,Anna Schuh,Tanya Siddiqi,Aaron Polliack,Constantine S. Tam,Deepali Suri,Mei Cheng,Fong Clow,Lori Styles,Danelle F. James,Thomas J. Kipps +33 more
TL;DR: Ibrutinib was superior to chlorambucil in previously untreated patients with CLL or small lymphocytic lymphoma, as assessed by progression-free survival, overall survival, response rate, and improvement in hematologic variables.
Journal ArticleDOI
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
Abstr Act,Sagar Lonial,Meletios A. Dimopoulos,Antonio Palumbo,Darrell White,Sebastian Grosicki,Ivan Spicka,Adam Walter‑Croneck,Philippe Moreau,Maria-Victoria Mateos,Hila Magen,Andrew Belch,Donna E. Reece,Meral Beksac,Andrew Spencer,Heather Oakervee,Robert Z. Orlowski,Masafumi Taniwaki,Christoph Röllig,Hermann Einsele,Ka Lung Wu,Anil K. Singhal,Jesús F. San Miguel,Morio Matsumoto,Jessica Katz,Eric Bleickardt,Valerie Poulart,Kenneth C. Anderson,Paul G. Richardson +28 more
TL;DR: Patients with relapsed or refractory multiple myeloma who received a combination of elotuzumab, lenalidomide, and dexamethasone had a significant relative reduction of 30% in the risk of disease progression or death.
Journal ArticleDOI
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study
Philippe Moreau,Halyna Pylypenko,Sebastian Grosicki,Ievgenii Karamanesht,Xavier Leleu,Maria Grishunina,Grigoriy B Rekhtman,Zvenyslava Masliak,Tadeusz Robak,Anna V Shubina,Bertrand Arnulf,Martin Kropff,James Cavet,Dixie-Lee Esseltine,Huaibao Feng,Suzette Girgis,Helgi van de Velde,William Deraedt,Jean-Luc Harousseau +18 more
TL;DR: The primary objective was to show non-inferiority of subcutaneous versus intravenous bortezomib in terms of overall response rate (ORR) after four cycles in patients with a diagnosis of measurable, secretory multiple myeloma who received one or more dose of drug.
Journal ArticleDOI
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Maria-Victoria Mateos,Meletios A. Dimopoulos,Michele Cavo,Kenshi Suzuki,Andrzej Jakubowiak,Stefan Knop,Chantal Doyen,Paulo Sérgio Lucio,Zsolt Nagy,Polina Kaplan,Ludek Pour,Mark Cook,Sebastian Grosicki,Andre Crepaldi,Anna Marina Liberati,Philip Campbell,Tatiana Shelekhova,Sung-Soo Yoon,Genadi Iosava,Tomoaki Fujisaki,Mamta Garg,Christopher Chiu,Jianping Wang,Robin Carson,Wendy Crist,William Deraedt,Huong Nguyen,Ming Qi,Jesús F. San-Miguel +28 more
TL;DR: Among patients with newly diagnosed multiple myeloma who were ineligible for stem‐cell transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a lower risk of disease progression or death than the same regimen without darumumab.
Journal ArticleDOI
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Meletios A. Dimopoulos,Dominik Dytfeld,Sebastian Grosicki,Philippe Moreau,Naoki Takezako,Mitsuo Hori,Xavier Leleu,Richard Leblanc,Kenshi Suzuki,Marc S. Raab,Paul G. Richardson,Mihaela Popa McKiver,Ying Ming Jou,Suresh Shelat,Michael Robbins,Brian Rafferty,Jesús F. San-Miguel +16 more
TL;DR: Among patients with multiple myeloma in whom treatment with lenalidomide and a proteasome inhibitor had failed, the risk of progression or death was significantly lower among those who received elotuzumab plus pomalidomides and dexamethasone than among thoseWho received pom Khalidomide plus dexamETHasone alone.